CLS Stock Recent News

Riding on a robust earnings surprise history and favorable Zacks Rank, CLS appears primed for further stock price appreciation.

In the closing of the recent trading day, Celestica (CLS) stood at $46.65, denoting a +0.43% change from the preceding trading day.

Celestica (CLS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

- CLS-AX is a Highly Potent Tyrosine Kinase Inhibitor Delivered Suprachoroidally Using Clearside's Proprietary SCS Microinjector ® -

Celestica (CLS) possesses solid growth attributes, which could help it handily outperform the market.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Riding on a robust earnings surprise history and favorable Zacks Rank, Celestica (CLS) appears primed for further stock price appreciation.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Recently, Zacks.com users have been paying close attention to Celestica (CLS). This makes it worthwhile to examine what the stock has in store.

Celestica continues to demonstrate strong revenue growth and substantial operating leverage as it capitalizes on secular trends in AI and data centers. The company's revenue and EBITDA growth are unmatched by industry peers, indicating that Celestica is gaining market share at the expense of its rivals. The management is confident that the company will be able to sustain strong growth momentum, which is evident from the full year guidance boost.